

Jonathon B Cohen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3699675/jonathon-b-cohen-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85
papers

2,045
citations

19
h-index

44
g-index

91
ext. papers

2,599
ext. citations

3.7
avg, IF

4.32
L-index

#	Paper	IF	Citations
85	Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CREWE): a multicentre cohort study.. <i>Lancet Haematology</i> , 2022 , 9, e289-e300	14.6	3
84	Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2200088	2.2	4
83	Phase II Study of Venetoclax in Combination with Obinutuzumab and Bendamustine in Patients with High Tumor Burden Follicular Lymphoma As Front Line Therapy (PrECOG 0403). <i>Blood</i> , 2021 , 138, 814-814	2.2	0
82	Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥5 Years Receiving Bendamustine-Rituximab. <i>Blood</i> , 2021 , 138, 3517-3517	2.2	0
81	Discontinuation Due to Toxicity Limits Treatment Duration of BTK Inhibitors in Non-Hodgkin Lymphoma. <i>Blood</i> , 2021 , 138, 4685-4685	2.2	
80	Understanding Factors That Determine Clinical Trial Enrollment for African American Patients with Lymphoma. <i>Blood</i> , 2021 , 138, 4965-4965	2.2	
79	Prognostic Value of Early PET in Patients with Aggressive Non-Hodgkin Lymphoma Treated with Anti-CD19 CAR T-Cell Therapy. <i>Blood</i> , 2021 , 138, 886-886	2.2	
78	Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Novel Comorbidity Measure, Predicts Outcomes in the Context of Targeted Agents and in a Large National Registry. <i>Blood</i> , 2021 , 138, 2637-2637	2.2	0
77	A Multicenter, Real World Analysis of Primary Central Nervous System Lymphoma in Those with and without Human Immunodeficiency Virus. <i>Blood</i> , 2021 , 138, 1457-1457	2.2	
76	Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices. <i>Blood</i> , 2021 , 138, 532-532	2.2	
75	Evaluation of Eligibility Criteria in First-Line Clinical Trials for Follicular Lymphoma: A MER/LEO Database Analysis. <i>Blood</i> , 2021 , 138, 338-338	2.2	
74	Genomic and Transcriptional Characterization of Primary Mediastinal Large B Cell Lymphoma. <i>Blood</i> , 2021 , 138, 2398-2398	2.2	
73	Sequencing of Novel Therapies for Mantle Cell Lymphoma. <i>Current Treatment Options in Oncology</i> , 2021 , 22, 118	5.4	0
72	Diagnostic retinal biopsy in the management of secondary non-CNS vitreoretinal lymphoma masquerading as viral retinitis: a case report. <i>International Journal of Retina and Vitreous</i> , 2021 , 7, 58	2.9	1
71	Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. <i>Blood Advances</i> , 2021 , 5, 1648-1659	7.8	6
70	Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1329-1338	2.2	19
69	Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. <i>European Journal of Haematology</i> , 2021 , 107, 301-310	3.8	1

68	Surveillance imaging during first remission in follicular lymphoma does not impact overall survival. <i>Cancer</i> , 2021 , 127, 3390-3402	6.4	5
67	Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma. <i>Blood Advances</i> , 2021 , 5, 3623-3632	7.8	1
66	Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. <i>American Journal of Hematology</i> , 2021 , 96, 1374-1384	7.1	2
65	Autologous Transplant versus Chimeric Antigen Receptor T-cell Therapy for Relapsed DLBCL in Partial Remission. <i>Blood</i> , 2021 ,	2.2	9
64	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. <i>Blood</i> , 2021 ,	2.2	6
63	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. <i>Blood Advances</i> , 2021 , 5, 5179-5189	7.8	0
62	Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2021 , 195, 757-763	4.5	2
61	Management of Older Adults with Mantle Cell Lymphoma. <i>Drugs and Aging</i> , 2020 , 37, 469-481	4.7	4
60	Initial Treatment of Early Stage and Low Tumor Burden Follicular Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020 , 34, 663-672	3.1	1
59	Ixazomib with or without Rituximab Following Immunochemotherapy and Autologous Stem Cell Transplant in Mantle Cell Lymphoma. <i>Blood</i> , 2020 , 136, 39-39	2.2	
58	Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era. <i>Blood</i> , 2020 , 136, 20-21	2.2	
57	Bendamustine, Obinutuzumab and Venetoclax As Induction Therapy for Untreated Mantle Cell Lymphoma. <i>Blood</i> , 2020 , 136, 33-34	2.2	1
56	Medical Simulation in Relapsed Follicular Lymphoma Improves Clinical Decision Making of Hematologists/Oncologists. <i>Blood</i> , 2020 , 136, 33-34	2.2	
55	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI) Predicts Survival and Tolerance of Ibrutinib Therapy in Patients with CLL: A Multicenter Retrospective Cohort Study. <i>Blood</i> , 2020 , 136, 1-3	2.2	
54	Beyond Mortality: Health-Related Quality of Life in Adolescent and Young Adult Patients with Lymphoma: A Longitudinal Study. <i>Blood</i> , 2020 , 136, 7-8	2.2	
53	Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. <i>Cancer</i> , 2020 , 126, 293-303	6.4	11
52	Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study. <i>Cancer</i> , 2020 , 126, 1235-1242	6.4	5
51	Is Limited-Stage Mantle Cell Lymphoma Curable and How Is It Best Managed?. <i>Hematology/Oncology Clinics of North America</i> , 2020 , 34, 849-859	3.1	1

50	Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3095-3106	2.2	78
49	Management of Relapsed Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20 Suppl 1, S98-S100	2	
48	Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. <i>Blood Advances</i> , 2020 , 4, 253-262	7.8	16
47	Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1859-1868	4.7	37
46	Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1997-2007	2.2	110
45	Racial and Socioeconomic Disparities in Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e312-e320	2	9
44	Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. <i>Journal of Clinical Oncology</i> , 2019 , 37, 471-480	2.2	44
43	Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019 , 134, 753-753	2.2	6
42	Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 6	22.4	15
41	Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. <i>Leukemia and Lymphoma</i> , 2019 , 60, 940-946	1.9	2
40	Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. <i>Cancer</i> , 2018 , 124, 2306-2315	6.4	18
39	Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2862-2870	1.9	8
38	Preliminary Clinical Results of a Phase 1 Study Evaluating the Safety and Anti-Tumor Activity of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ B-Cell Lymphoma. <i>Blood</i> , 2018 , 132, 2966-2966	2.2	1
37	Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 2157-2157	2.2	1
36	Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1163-1171	4.7	72
35	Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility. <i>Leukemia and Lymphoma</i> , 2018 , 59, 888-895	1.9	9
34	Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2018 , JCO1800359	2.2	12
33	The association of physical activity before and after lymphoma diagnosis with survival outcomes. <i>American Journal of Hematology</i> , 2018 , 93, 1543-1550	7.1	8

32	Novel therapies for relapsed/refractory aggressive lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2018 , 2018, 75-82	3.1	6
31	Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. <i>Hematological Oncology</i> , 2017 , 35, 528-535	1.3	37
30	A phase 2 trial of alisertib in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1-2	1.9	3
29	Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 512-525	7.1	11
28	Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. <i>American Journal of Hematology</i> , 2017 , 92, 161-170	7.1	43
27	Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study. <i>Blood</i> , 2017 , 130, 651-651	2.2	23
26	Nivolumab for classical Hodgkin lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. <i>Lancet Oncology</i> , 2016 , 17, 1283-94	21.7	643
25	Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma. <i>Cancer</i> , 2016 , 122, 2356-63	6.4	40
24	De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. <i>American Journal of Hematology</i> , 2016 , 91, 395-9	7.1	32
23	A Clinician Approach to Double-Hit Lymphoma: Identification, Evaluation, and Management. <i>Journal of Oncology Practice</i> , 2016 , 12, 232-8	3.1	9
22	Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E). <i>Blood</i> , 2016 , 128, 1106-1106	2.2	32
21	GIFT4 fusokine converts leukemic B cells into immune helper cells. <i>Journal of Translational Medicine</i> , 2016 , 14, 106	8.5	7
20	Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1543-1551	4.7	34
19	Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 2091-2099	4.7	45
18	Next-generation surveillance strategies for patients with lymphoma. <i>Future Oncology</i> , 2015 , 11, 1977-913.6		13
17	Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 278-285.e1	2	16
16	Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 514-8	2	3
15	Role of allogeneic stem cell transplantation in mantle cell lymphoma. <i>European Journal of Haematology</i> , 2015 , 94, 290-7	3.8	8

14	A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2015 , 171, 539-46	4.5	11
13	Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1605-11	4.7	28
12	Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412). <i>Blood</i> , 2015 , 126, 585-585	2.2	23
11	Deferred Treatment Is Associated with Improved Overall Survival in Patients with Newly Diagnosed Mantle Cell Lymphoma. <i>Blood</i> , 2015 , 126, 2717-2717	2.2	
10	Suvmax in 18-Fluorodeoxyglucose PET/CT Potentially Predict the Estimation of a Positive Biopsy in Cases of Lymphoma. <i>Blood</i> , 2015 , 126, 5043-5043	2.2	
9	Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival. <i>Cancer</i> , 2014 , 120, 1677-85	6.4	43
8	Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14, 460-467.e2	2	69
7	Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. <i>Blood</i> , 2014 , 124, 2354-61	2.2	306
6	Optimal disease surveillance strategies in non-Hodgkin lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2014 , 2014, 481-7	3.1	11
5	Peripheral T-cell lymphoma: what's the role for transplant?. <i>Oncology</i> , 2013 , 27, 891-2	1.8	
4	Hearing Loss due to Infiltration of the Tympanic Membrane by Chronic Lymphocytic Leukemia. <i>Case Reports in Hematology</i> , 2012 , 2012, 589718	0.7	3
3	Evaluation and management of lymphoma and leukemia in pregnancy. <i>Clinical Obstetrics and Gynecology</i> , 2011 , 54, 556-66	1.7	13
2	The Prognostic Value of FDG PET/CT Prior to Autologous Stem Cell Transplant in Mantle Cell Lymphoma. <i>Blood</i> , 2011 , 118, 3113-3113	2.2	
1	Somatic Hypermutation in Mantle Cell Lymphoma. <i>Blood</i> , 2011 , 118, 5189-5189	2.2	